Skip to main content

Table 1 Baseline levels of total cholesterol (TC), HDL cholesterol (HDL), LDL cholesterol (LDL), TC/HDL ratio, triglycerides (TG) and Framingham score (FRS) across groups. Variable are expressed as means (±SD) or medians (Q1-Q3)

From: Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Variable

Switches from 2NRTI + EFV to

Switches from 2NRTI + PI/r to

DTG

EVG

RPV

DTG

EVG

RPV

TC (mg/dl)

198.5 (41.6)

207.4 (40.7)

196.5 (38.0)

209.9 (41.0)

203.7 (43.9)

189.2 (47.1)

HDL (mg/dl)

53.5 (16.7)

49.3 (14.4)

48.8 (13.8)

48.8 (14.7)

43.5 (12.3)

48.8 (21.0)

TC/HDL (mg/dl)

3.93 (1.1)

4.4 (1.1)

4.3 (1.4)

4.65 (1.6)

4.98 (1.6)

4.2 (1.3)

LDL (mg/dl)

117.0 (39.4)

128.2 (32.6)

120.3 (35.5)

126.0 (33.7)

123.5 (38.2)

111.1 (39.5)

TG (mg/dl)

114 (91.5–153.5)

126.5 (106–171)

109 (77–160)

142 (84–215)

150 (112–204)

117 (85–189)

FRS (%)

12.2 (6.7–25.3)

6.7 (3.9–9.4)

7.9 (4.7–13.2)

9.4 (4.5–21.6)

9.4 (4.5–15.6)

7.3 (3.3–13.2)

  1. NRTI nucleoside reverse transcriptase inhibitors, EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine